These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 25084170)
1. Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. Dago AE; Stepansky A; Carlsson A; Luttgen M; Kendall J; Baslan T; Kolatkar A; Wigler M; Bethel K; Gross ME; Hicks J; Kuhn P PLoS One; 2014; 9(8):e101777. PubMed ID: 25084170 [TBL] [Abstract][Full Text] [Related]
2. Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis. Greene SB; Dago AE; Leitz LJ; Wang Y; Lee J; Werner SL; Gendreau S; Patel P; Jia S; Zhang L; Tucker EK; Malchiodi M; Graf RP; Dittamore R; Marrinucci D; Landers M PLoS One; 2016; 11(11):e0165089. PubMed ID: 27851748 [TBL] [Abstract][Full Text] [Related]
3. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765 [TBL] [Abstract][Full Text] [Related]
4. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. Gupta S; Li J; Kemeny G; Bitting RL; Beaver J; Somarelli JA; Ware KE; Gregory S; Armstrong AJ Clin Cancer Res; 2017 Mar; 23(5):1346-1357. PubMed ID: 27601596 [No Abstract] [Full Text] [Related]
5. Androgen receptor expression on circulating tumor cells in metastatic breast cancer. Fujii T; Reuben JM; Huo L; Espinosa Fernandez JR; Gong Y; Krupa R; Suraneni MV; Graf RP; Lee J; Greene S; Rodriguez A; Dugan L; Louw J; Lim B; Barcenas CH; Marx AN; Tripathy D; Wang Y; Landers M; Dittamore R; Ueno NT PLoS One; 2017; 12(9):e0185231. PubMed ID: 28957377 [TBL] [Abstract][Full Text] [Related]
6. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. Magbanua MJ; Sosa EV; Scott JH; Simko J; Collins C; Pinkel D; Ryan CJ; Park JW BMC Cancer; 2012 Feb; 12():78. PubMed ID: 22373240 [TBL] [Abstract][Full Text] [Related]
7. Genomic Analysis of Localized High-Risk Prostate Cancer Circulating Tumor Cells at the Single-Cell Level. Rangel-Pozzo A; Liu S; Wajnberg G; Wang X; Ouellette RJ; Hicks GG; Drachenberg D; Mai S Cells; 2020 Aug; 9(8):. PubMed ID: 32784507 [TBL] [Abstract][Full Text] [Related]
8. Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer. Malihi PD; Graf RP; Rodriguez A; Ramesh N; Lee J; Sutton R; Jiles R; Ruiz Velasco C; Sei E; Kolatkar A; Logothetis C; Navin NE; Corn P; Aparicio AM; Dittamore R; Hicks J; Kuhn P; Zurita AJ Clin Cancer Res; 2020 Aug; 26(15):4143-4153. PubMed ID: 32341031 [TBL] [Abstract][Full Text] [Related]
9. Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients. Worroll D; Galletti G; Gjyrezi A; Nanus DM; Tagawa ST; Giannakakou P Phys Biol; 2019 Mar; 16(3):036003. PubMed ID: 30763921 [TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683 [TBL] [Abstract][Full Text] [Related]
11. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. Gupta S; Vanderbilt C; Abida W; Fine SW; Tickoo SK; Al-Ahmadie HA; Chen YB; Sirintrapun SJ; Chadalavada K; Nanjangud GJ; Bialik A; Morris MJ; Scher HI; Ladanyi M; Reuter VE; Gopalan A Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):507-516. PubMed ID: 32094488 [TBL] [Abstract][Full Text] [Related]
13. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641 [TBL] [Abstract][Full Text] [Related]
14. Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide. Pal SK; He M; Chen L; Yang L; Pillai R; Twardowski P; Hsu J; Kortylewski M; Jones JO Urol Oncol; 2018 Apr; 36(4):162.e1-162.e6. PubMed ID: 29289429 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns. De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311 [TBL] [Abstract][Full Text] [Related]
16. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Jiang Y; Palma JF; Agus DB; Wang Y; Gross ME Clin Chem; 2010 Sep; 56(9):1492-5. PubMed ID: 20581083 [TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010 [No Abstract] [Full Text] [Related]
18. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Nakazawa M; Lu C; Chen Y; Paller CJ; Carducci MA; Eisenberger MA; Luo J; Antonarakis ES Ann Oncol; 2015 Sep; 26(9):1859-1865. PubMed ID: 26117829 [TBL] [Abstract][Full Text] [Related]
19. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression. Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201 [TBL] [Abstract][Full Text] [Related]
20. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. Jiang R; Lu YT; Ho H; Li B; Chen JF; Lin M; Li F; Wu K; Wu H; Lichterman J; Wan H; Lu CL; OuYang W; Ni M; Wang L; Li G; Lee T; Zhang X; Yang J; Rettig M; Chung LW; Yang H; Li KC; Hou Y; Tseng HR; Hou S; Xu X; Wang J; Posadas EM Oncotarget; 2015 Dec; 6(42):44781-93. PubMed ID: 26575023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]